An announcement from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., has reported a strong financial performance for the year ended December 31, 2024. The company achieved a notable increase in revenue and net profit, with revenue rising by 25.57% and net profit attributable to shareholders growing by 35.29%. This financial growth highlights Dong-E-E-Jiao’s robust market positioning and operational efficiency, potentially benefiting stakeholders and enhancing the company’s competitive edge in the traditional Chinese medicine sector.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. is involved in the pharmaceutical industry, with a focus on manufacturing and distributing pharmaceutical products. The company holds a significant stake in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange, which specializes in the production of traditional Chinese medicine products.
YTD Price Performance: -2.96%
Average Trading Volume: 2,135
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €4.2B
For an in-depth examination of 3320 stock, go to TipRanks’ Stock Analysis page.